SEC Filings

SEC Filings are regulatory documents that Nanobiotix must submit to the Securities and Exchange Commission (SEC) on a regular basis. The purpose is to provide transparency and information to investors, analysts, and regulators.
14 result
Form 6-K - Nanobiotix announces first quarter operational and financial updates
Form 6-K - Nanobiotix to present four posters including updates from priority head and neck cancer and immunotherapy development pathways
FORM 6-K - Nanobiotix Combined Shareholders Meeting To Be Held April 28, 2021
FORM 6-K - Nanobiotix Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
FORM 6-K - Nanobiotix Reports Full Year 2020 Financial Results And Highlights Operational Progress
FORM 6-K - Nanobiotix and Pharmaengine mutually agree to conclude collaboration
FORM 6-K - Preclinical data presented at AACR virtual special conference
FORM 6-K - Nanobiotix announces 2020 Q4 and annual revenues
FORM 6-K - Nanobiotix announces first patient injected with NBTXR3 in esophageal cancer
FORM 6-K - Nanobiotix subsidiary Curadigm secures new collaboration agreement with Sanofi focused on gene therapy pipeline
FORM 6-K - Nanobiotix announces positive first results for novel NBTXR3 in rectal cancer study